Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development ...

The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...

Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), with a price target ...

Among 64 patients who received immune checkpoint inhibitors, 78% had downstaging of their liver tumor to within Milan ...

SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] The Subject Expert Commit ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Opdivo plus Yervoy for the ...